Pembrolizumab-Induced Pancreatic Exocrine Insufficiency Complicated by Severe Hepatic Steatosis.

hepatic steatosis immune-related adverse event immunotherapy pancreatic exocrine insufficiency pembrolizumab

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jul 2022
Historique:
accepted: 05 07 2022
entrez: 8 8 2022
pubmed: 9 8 2022
medline: 9 8 2022
Statut: epublish

Résumé

Anti-programmed death receptor-1 (anti-PD-1) monoclonal antibodies (mAbs) are used to treat an increasing range of cancers. However, the distinct toxicity profile of immune-related adverse events (irAEs) is a frequent drawback of their clinical application. Among the more common irAEs are hepatitis and colitis, which are diagnosed and graded in patients based on elevated serum liver enzyme levels and increased stool frequency, respectively, and both of which often require treatment with high-dose corticosteroids. Herein, we describe the case of a patient who developed severe transaminase elevation and diarrhoea due to an unusual irAE, which was successfully treated without corticosteroids.

Identifiants

pubmed: 35936135
doi: 10.7759/cureus.26596
pmc: PMC9354921
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e26596

Informations de copyright

Copyright © 2022, Hong et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ann Gastroenterol Surg. 2017 Jul 20;1(3):226-231
pubmed: 29863141
Am J Gastroenterol. 2008 Jan;103(1):245-6
pubmed: 18184133
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Surg Oncol. 2018 Jun;117(7):1548-1555
pubmed: 29572825
Eur J Cancer. 2016 Jun;60:190-209
pubmed: 27085692
J Surg Oncol. 2014 Nov;110(6):720-6
pubmed: 24965234
J Hepatobiliary Pancreat Sci. 2014 Mar;21(3):186-92
pubmed: 23798362
Eur J Cancer. 2018 May;95:123-126
pubmed: 29530539
Ann Oncol. 2017 Feb 1;28(2):434-435
pubmed: 27864215
Dig Surg. 2014;31(4-5):359-65
pubmed: 25503526
Eur J Cancer. 2017 Dec;87:216-218
pubmed: 28993041
Clin J Gastroenterol. 2013 Dec;6(6):470-5
pubmed: 26182139
Scand J Surg. 2017 Sep;106(3):224-229
pubmed: 27651297
J Gastroenterol. 2011 Jun;46(6):758-68
pubmed: 21267748
Immunology. 2020 Feb;159(2):167-177
pubmed: 31646612
Pancreas. 2016 Mar;45(3):362-9
pubmed: 26495776
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
Immunotherapy. 2018 Mar;10(3):171-175
pubmed: 29370723
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Eur J Cancer. 2018 Nov;104:243-246
pubmed: 30454710

Auteurs

Alex S Hong (AS)

Gastroenterology and Hepatology, Imperial College School of Medicine, London, GBR.

Naveed Sarwar (N)

Medical Oncology, Department of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, GBR.

Robert D Goldin (RD)

Section for Pathology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, GBR.

Ameet Dhar (A)

Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.

Lucia A Possamai (LA)

Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.

Classifications MeSH